3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/08/26	KRW 6,310.00	-0.63%	77,890
10/08/26	KRW 6,350.00	+4.44%	131,741
07/08/26	KRW 6,080.00	-3.18%	53,586
06/08/26	KRW 6,280.00	+1.62%	142,628
05/08/26	KRW 6,180.00	+3.52%	136,245

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 10/08/2026			5-day change	1st Jan Change
6,350.00 ^KRW	+4.44%		+21.65%	-65.17%

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	201B 142M 123M 115M 105M 197M 13.51B 200M 1.34B 527M 6.76B 532M 520M 22.5B	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	184M 130K 112K 105K 95.92K 181K 12.37M 184K 1.23M 483K 6.19M 487K 476K 20.61M	EV / Sales 2025	49x	EV / Sales 2026 *	-
Free-Float	75.48%	Yield 2025 *	-	Yield 2026 *	-

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
23/04	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
09/04	3Billion Inc wins 955 million won order	RE
23/03	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03/25	3Billion Inc Wins 655 Million Won Order	RE

1 day	+4.44%
1 week	+21.65%
Current month	+23.54%
1 month	+7.63%
3 months	-45.35%
6 months	-53.51%
Current year	-65.17%

3billion, Inc. Stock

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news : 3billion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	5,830	6,560
1 month	4,260	6,560
Current year	4,260	18,690
1 year	4,260	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	10/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	01/10/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	01/08/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	10/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	10/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	18/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/4/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
7/3/25	Soon-Il Park	Fiscal year	Chief Financial Officer	40,000	0.1262%
7/3/25	Ki-hyun Kang	Fiscal year		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	+4.44%	+21.65%	+0.47%	-	143M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.32%	+5.44%	+113.05%	+310.87%	4.06B
VERACYTE, INC.	+0.67%	+0.17%	+66.10%	+84.85%	3.72B
IOVANCE BIOTHERAPEUTICS, INC.	+1.02%	+49.00%	+229.77%	-7.98%	2.9B
CAREDX, INC.	+0.92%	+0.47%	+301.95%	+431.57%	2.44B
BGI GENOMICS CO., LTD.	+1.83%	+7.08%	-22.02%	-32.36%	2.31B
FREENOME, INC.	+2.02%	+5.54%	+9.93%	-	1.31B
SEEGENE, INC.	+6.40%	+15.17%	+2.33%	+32.54%	988M
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.08%	-5.52%	+194.90%	-41.25%	904M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+5.70%	+10.16%	-32.72%	+0.34%	541M
Average	+2.52%	+16.79%	+86.38%	+97.32%	1.93B
Weighted average by Cap.	+1.74%	+22.92%	+115.40%	+141.41%

	2025	2026 *
Net sales	10.8B 7.62M 6.59M 6.16M 5.63M 10.62M 726M 10.78M 72.28M 28.36M 363M 28.6M 27.98M 1.21B	-
Net income	-5.8B -4.09M -3.54M -3.31M -3.03M -5.7M -390M -5.79M -38.81M -15.23M -195M -15.36M -15.02M -650M	-
Net Debt	-16.9B -11.92M -10.32M -9.64M -8.81M -16.61M -1.14B -16.87M -113M -44.38M -569M -44.76M -43.78M -1.89B	-